Cardiac Health Protocol

Overview

Cardiovascular disease remains the leading cause of death globally. The dominant risk levers are well established — blood pressure, apoB-containing lipoprotein burden, glucose regulation, body composition, training status, sleep, and smoking. Peptides are not a replacement for these fundamentals and not a replacement for statin or PCSK9 therapy when indicated.

This protocol frames peptides as adjunctive support for general cardiovascular resilience and post-event recovery. TB-500 has preclinical data on cardiac tissue repair and vascular remodeling. BPC-157 has vasoprotective effects in animal models. This protocol is not a substitute for cardiology care, acute event management, or evidence-based risk-factor pharmacotherapy.

Compounds Involved

TB-500

Thymosin β4 and its TB-500 fragment have been studied in cardiac ischemia-reperfusion and post-infarct remodeling models. Human data are limited and it is not approved for cardiac indications. Use here is speculative and adjunctive.

BPC-157

BPC-157 has shown vasoprotective and NO-modulating effects in animal studies. In this protocol it is used at conservative doses as a general vascular support tool.

Protocol Structure

Phase 1 — Establish Baseline and Optimize Fundamentals (Weeks 1–8)

No peptide stack substitutes for this phase. Data every cardiologist will recognize:

• Lipid panel with apoB; Lp(a) measured once in lifetime
• Blood pressure (home cuff, multiple readings, averaged)
• HbA1c, fasting insulin
• hs-CRP
• Consider CAC (coronary artery calcium) score in adults >40 without established disease
• ECG and echocardiogram if symptoms or risk factors warrant

Risk factor optimization:

• Blood pressure — target <120/80 unless otherwise directed; lifestyle + antihypertensives as needed
• apoB / LDL-C — target depends on risk; often <70 mg/dL LDL-C for secondary prevention
• Glucose — address insulin resistance aggressively; see Metabolic Syndrome Protocol
• Body composition — waist circumference <40 in men, <35 in women
• Aerobic training — 150+ minutes zone 2/week, plus VO2max work
• Resistance training — 2–3 sessions/week
• Smoking — cessation is non-negotiable
• Sleep — diagnose and treat sleep apnea; 7–9 hours

Phase 2 — Adjunctive Peptide Layer (Weeks 9–20)

• BPC-157 250 mcg/day subcutaneous
• TB-500 2 mg subcutaneous 2x/week (e.g., Monday and Thursday)
• Omega-3 3 g EPA+DHA/day
• CoQ10 100 mg/day (200 mg if on statin, as statins deplete CoQ10)
• Magnesium 300 mg/day, particularly if deficient on testing

Phase 3 — Maintenance

• Continue foundational nutrition, training, and risk-factor pharmacotherapy indefinitely
• Cycle peptides: 12 weeks on, 4–8 weeks off
• Retest lipid panel, hs-CRP, and blood pressure every 3–6 months
• CAC progression (if previously measured) should be followed on a 3–5 year interval

Post-Event Recovery Considerations

For patients recovering from MI, CABG, or similar events, any peptide use must be coordinated with the cardiology and surgical team. Timing relative to anticoagulation, antiplatelet therapy, and wound healing matters.

Important Considerations

• This protocol does not replace, delay, or substitute for cardiology evaluation, acute care, or evidence-based pharmacotherapy (statins, antihypertensives, antiplatelets, PCSK9 inhibitors as indicated).
• Chest pain, new shortness of breath, syncope, or exertional symptoms are not "peptide problems" — seek emergency evaluation.
• TB-500 and BPC-157 are not FDA-approved for cardiac indications and lack robust human outcome data.
• Omega-3 supplementation at high doses can modestly increase bleeding time; discuss with clinician if on anticoagulation.
• CoQ10 is particularly valuable for patients on statins who experience muscle symptoms.
• Athletes with LV hypertrophy, arrhythmia history, or family history of sudden cardiac death require specialist clearance before any performance peptide protocol.
• Injection site bruising in patients on anticoagulants or antiplatelets may be more prominent; consider subcutaneous sites in low-vascularity regions.

Disclaimer

This content is for educational and informational purposes only and is not medical advice. Cardiovascular disease is life-threatening and requires evaluation and ongoing care by qualified medical professionals. The peptides discussed are not FDA-approved for cardiac indications and their efficacy and safety in cardiac patients has not been established. Do not discontinue prescribed cardiovascular medications or delay care for cardiac symptoms. Pepperpedia does not endorse the acquisition or use of unapproved substances.